Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Ford

Showing results (31-40 of 508) with videos related to

Pageof 51
Sort By:
European Heart Journal|September 2, 2009
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trialKim Fox, Ian Ford, Ph Gabriel Steg, et al.
International Journal of Cardiology|February 1, 2017
Comments on meta-analysis of ivabradine as adjuvant treatment for chronic heart failure by Mizzaci et alKarl Swedberg, Michael Böhm, Jeffrey S Borer, et al.
JACC. Heart Failure|March 7, 2015
Effect of ivabradine on early readmissions after hospitalization for worsening heart failureJeffrey S Borer, Michael Böhm, Ian Ford, et al.
BMJ Open|February 1, 2013
Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)Thomas M Macdonald, Isla S Mackenzie, Li Wei, et al.
The American Journal of Medicine|February 19, 2018
The ReplyPaul R Kalra, Nicola Greenlaw, Ian Ford, et al.
Current Medical Research and Opinion|September 12, 2015
Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patientsJennifer K Rogers, Adrian Kielhorn, Jeffrey S Borer, et al.
European Heart Journal|September 20, 2015
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY studyKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
Plos One|April 9, 2013
Outcomes of induction of labour in women with previous caesarean delivery: a retrospective cohort study using a population databaseSarah J Stock, Evelyn Ferguson, Andrew Duffy, et al.
The New England Journal of Medicine|September 2, 2014
Ivabradine in stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
Journal of the American College of Cardiology|May 24, 2012
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) studyKarl Swedberg, Michel Komajda, Michael Böhm, et al.
Pageof 51

Showing results (31-40 of 508) with videos related to

Sort By:
Pageof 51
European Heart Journal|September 2, 2009
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trialKim Fox, Ian Ford, Ph Gabriel Steg, et al.
International Journal of Cardiology|February 1, 2017
Comments on meta-analysis of ivabradine as adjuvant treatment for chronic heart failure by Mizzaci et alKarl Swedberg, Michael Böhm, Jeffrey S Borer, et al.
JACC. Heart Failure|March 7, 2015
Effect of ivabradine on early readmissions after hospitalization for worsening heart failureJeffrey S Borer, Michael Böhm, Ian Ford, et al.
BMJ Open|February 1, 2013
Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)Thomas M Macdonald, Isla S Mackenzie, Li Wei, et al.
The American Journal of Medicine|February 19, 2018
The ReplyPaul R Kalra, Nicola Greenlaw, Ian Ford, et al.
Current Medical Research and Opinion|September 12, 2015
Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patientsJennifer K Rogers, Adrian Kielhorn, Jeffrey S Borer, et al.
European Heart Journal|September 20, 2015
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY studyKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
Plos One|April 9, 2013
Outcomes of induction of labour in women with previous caesarean delivery: a retrospective cohort study using a population databaseSarah J Stock, Evelyn Ferguson, Andrew Duffy, et al.
The New England Journal of Medicine|September 2, 2014
Ivabradine in stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
Journal of the American College of Cardiology|May 24, 2012
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) studyKarl Swedberg, Michel Komajda, Michael Böhm, et al.
Pageof 51